Table 1.
no. | linker | linker length (atoms) | estimated linker length (Å) | IC50 (nM) of CCK(6)b
|
fold increase | IC50 (nM) of MSH(7)b
|
fold increase | ||
---|---|---|---|---|---|---|---|---|---|
CCK-2Rc | dual expressione | hMC4Rd | dual expressione | ||||||
5a | -[PG]3- | 18 | ≤13 | 11 (8.3–15) | 1.4 (1.0–2.0) | 8 | 11 (8.9–12) | 1300 (880–1900) | 0 |
5b | -[PG]6- | 36 | ≤25 | 46 (40–52) | 2.3 (1.8–2.9) | 20 | 110 (85–140) | 1000 (690–1500) | 0.1 |
5c | -[PG]9- | 54 | ≤35 | 320 (240–420) | 170 (130–240) | 2 | 460 (250–850) | 530 (180–1500) | 0.9 |
5d | -[PG]12- | 72 | ≤45 | 50 (43–58) | 6.9 (5.6–8.6) | 7 | 28 (23–33) | 980 (250–3900) | 0 |
5e | -[PG]15 | 90 | ≤55 | 230 (190–290) | 55 (43–70) | 4 | 680 (310–1500) | 3500 (1300–9500) | 0.2 |
8a | -PEGO- | 20 | ≤18 | 11 (9.0–13) | 0.50 (0.31–0.82) | 22 | 28 (22–34) | 250 (210–300) | 0.1 |
8b | -PEGO-PEGO- | 40 | ≤36 | 50 (41–62) | 4.5 (3.4–5.8) | 11 | 60 (49–75) | 320 (260–400) | 0.2 |
12a | -PEGO-[PG]3-PEGO- | 58 | ≤46 | 150 (120–180) | 6.3 (5.0–7.9) | 24 | 390 (89–1700) | 1600 (560–4700) | 0.2 |
12b | -PEGO-[PG]6-PEGO- | 76 | ≤56 | 72 (56–94) | 20 (15–26) | 4 | 230 (160–340) | 21 (17–27) | 11 |
12c | -PEGO-[PG]12-PEGO- | 112 | ≤76 | 130 (110–150) | 38 (29–50) | 3 | 10 (6.7–16) | 32 (25–39) | 0.3 |
12d | -PEGO-[PG]18-PEGO- | 148 | ≤96 | 160 (130–200) | 93 (78–110) | 2 | 35 (26–47) | 28 (21–40) | 1.3 |
The IC50 values of Ac-MSH(7)-NH2 and Ac-CCK(6)-NH2 are 39 ± 4 nM and 26 ± 4 nM, respectively. “Fold Increase” is the ratio of IC50 values between single- and dual-expressing cell lines.
IC50 concentration in nM from at least 4 independent experiments reported. Values in parentheses represent the 95% confidence intervals of the IC50 values.
Binding data from competition with Eu-DTPA-CCK-8 (unsulfated) against CCK-2R expressing cells.
Binding data from competition with Eu-DTPA-NDP-α-MSH against hMC4R expressing cells.
Binding data from competition with either Eu-DTPA-CCK-8 (unsulfated) or Eu-DTPA-NDP-α-MSH against cells expressing both CCK-2R and hMC4R.